As pharmaceutical supply chains evolve, India has an opportunity to transform its reliance on imported active pharmaceutical ingredients into a new era of manufacturing leadership, scientific innovati...
Executive Summary India has emerged as a major force in the global pharmaceutical industry, supported by its extensive manufacturing infrastructure, technical expertise and strong presence acros...
Key Highlights: Implications: Dr. Reddy’s has secured CDSCO approval for its abatacept biosimilar (250 mg IV) for adults with moderate‑to‑severe active rheumatoid arthritis and activ...
Key Highlights: Implications: The USFDA’s EIR and VAI classification provide regulatory closure for Strides Pharma’s Bengaluru facility following the five observations issued during the May 2026 inspe...
Key Highlights: Implications: Piramal Pharma’s move to 74% ownership of Yapan Bio for ₹76 crore turns the Hyderabad CDMO into a subsidiary, giving Piramal tighter control over Yapan’s process developm...
Key Highlights: Implications: Optimus Pharma’s DCGI approval for Tapinarof Cream 1% gives India its first locally manufactured, non‑steroidal topical for adult plaque psoriasis, offering dermatologist...
Key Highlights: Implications: Biodeal’s ₹385 crore raise gives it the capital to scale up manufacturing, add new products, and enter more regulated markets, which should help it win bigger, longer-ter...
Key Highlights: Implications: The deal adds ~$90–100 million of annualized revenue visibility from 2029, diversifies Gland’s customer base, and strengthens its credibility as a o...
Key Highlights: Implications: The new cGMP/US FDA/EU-compliant suite at Gland’s Visakhapatnam JNPC site, adding ~1,400 kg/year of sterile API capacity, should help both companies capture m...
Key Highlights: Implications: By adding the NSE to its existing BSE listing, Fermenta can attract more institutional and retail participation, which may support tighter spr...
